Prof Richard Pearson
Honorary (Professorial Fellow)
The Sir Peter MacCallum Department of Oncology
203 Scholarly works
22 Projects
HIGHLIGHTS
2025
Journal article
Investigating Ribosome-Targeting Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma
DOI: 10.1016/s2152-2650(25)03697-32025
Journal article
Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer
DOI: 10.1038/s41420-025-02716-12024
Journal article
Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins
DOI: 10.1186/s13059-024-03247-12020
Research Grant
Combinatorial Targeting of Cellular “Housekeeping” Processes to Treat Cancer.
2019
Research Grant
Targeting Nucleolar Dna Damage Response as a Novel Therapeutic strategy for High Grade Serous Ovarian Cancer
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2014
Journal article
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
DOI: 10.1158/2159-8290.CD-13-0440
RECENT SCHOLARLY WORKS
2024
Journal article
CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition
DOI: 10.1158/1538-8514.SYNTHLETH24-PR0052024
Journal article
Targeting the ribosome to treat multiple myeloma
DOI: 10.1016/j.omton.2024.2007712024
Journal article
ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia
DOI: 10.1126/sciadv.adj88032023
Journal article
Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments
DOI: 10.1038/s41467-023-37822-02023
Other
Data from CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition
DOI: 10.1158/1535-7163.c.6543495.v12023
Other
Data from Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression
DOI: 10.1158/0008-5472.c.65119532023
Conference Proceedings
SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR )/HER2-breast cancer
DOI: 10.1158/1538-7445.SABCS22-P5-02-16
RECENT PROJECTS
2013
Research Grant
Establishment of Acrf Advanced Centre for Cancer Cell Isolation and Imaging